GlassScriptPhysician profile
Alyssa Nicole Moore
NPI 1093127615
$1,889.01
in general payments reported to CMS, 2019-2025
21 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $96.64 · 2024: $357 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $504.63 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Axsome Therapeutics, INC. | $246.35 | 2025 | Auvelity |
| Abbvie INC. | $226.67 | 2025 | |
| Novo Nordisk INC | $138.69 | 2025 | Wegovy, Ozempic, Rybelsus |
| Braeburn INC. | $115.03 | 2024 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.79 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $71.08 | 2025 | Rexulti |
| Ardelyx, INC. | $62.59 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $62.02 | 2024-2025 | Voquezna |
| Lundbeck LLC | $59.86 | 2025 | Vyepti, Rexulti |
| Exact Sciences Corporation | $59.05 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $45.66 | 2025 | |
| Sumitomo Pharma America, INC. | $40.02 | 2025 | Gemtesa |
| Amgen INC. | $37.55 | 2024-2025 | Otezla, Repatha, Repatha |
| Fidia Pharma USA INC. | $33.41 | 2025 | Hymovis, Triluron |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.98 | 2025 | Camzyos |
| Merck Sharp & Dohme LLC | $16.94 | 2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $16.81 | 2025 | |
| Lilly USA, LLC | $16.06 | 2025 | Mounjaro, Zepbound |
| Insulet Corporation | $16.01 | 2025 | Omnipod |
| Abbott Laboratories | $13.81 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.